Published by Coherent Market Insights
Posted on September 30, 2021
Pediatric Clinical Trials Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Pediatric Clinical Trials Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/397
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc., Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol – Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Shire plc., and Vertex Pharmaceuticals Inc.
Increasing regulatory approvals of new pediatric drugs is expected to augment the market growth.
Key players in the market are focused on launching and approval of novel pediatric drugs, in order to cater to unmet needs of pediatric patients, which are expected to boost the market growth. Moreover, robust product pipeline is expected to drive the market growth. For instance, in December 2018, Merck and Company received the U.S. Food and Drugs Administration (FDA) approval for its Vaxelis, which is indicated for the treatment of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type B. This helped the company to enhance its product portfolio in the pediatric segment. Additionally, in December 2018, Servier Laboratories received FDA approval for Asparlas (calaspargase pegol-mknl), an asparagine specific enzyme indicated for the treatment of acute lymphoblastic leukemia in pediatrics and young adults, which is expected to help the company to enhance its product portfolio in pediatric therapy segment. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients suffered from diabetes, globally in 2017, of which one million people (children and adolescents below 20 years of age) were suffered from type 1 diabetes, with around 150,000 new cases reported, annually.
Browse 38 Market Data Tables and 34 Figures spread through 277 Pages and in-depth TOC on ‘Pediatric Clinical Trials Market’- Global Forecast to 2026, by Clinical Trial Phase (Pre-clinical, Phase I, Phase II, and Phase III), by Study Design (Interventional, (Randomized Trial, Non-randomized Trial, Crossover Trial) and Observational), by Medical Condition (Neuropsychiatric, Conditions, Infectious Diseases, Maternal and Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer, Digestive Diseases, Diabetes, Nutritional Deficiencies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Major market players are focusing on adopting strategies such as mergers, acquisitions, and collaborations to strengthen their market position. For instance, in April 2017, Charles River entered into a strategic collaboration with Nimbus Therapeutics that is engaged in advancing new programs in immunology, metabolic disorders, and oncology from the discovery phase to Investigational New Drug (IND) submission.
Key Takeaways of the Pediatric Clinical Trials Market:
The global pediatric clinical trials market is expected to exhibit a CAGR of 8.8% over the forecast period, attributed to robust product pipeline and increasing regulatory approval of new pediatric drugs
Among clinical trial phase, pre-clinical segment held a dominant position in the pediatric clinical trials market in 2018, attributed to safety and efficacy concerns about new molecules or drugs, as every new molecule must go through pre-clinical study
Among study design, randomized trial segment held a dominant position in the pediatric clinical trials market in 2018, as randomized trial study design eliminates the chance of biasness in clinical trials and is considered as the most favorable study design
Among medical condition, neuropsychiatric conditions segment held a dominant position in the pediatric clinical trials market in 2018, attributed to increasing number of mental disorders in children and adolescents. Mental disorders mainly affect children below age of 14 years.
Buy This Premium Report Of Pediatric Clinical Trials Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/397
In this study, the years considered to estimate the market size of Pediatric Clinical Trials are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Pediatric Clinical Trials Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Pediatric Clinical Trials Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Pediatric Clinical Trials Market Share Is Estimated to Grow at a CAGR of 9.0% By 2027 | Future Growth Analysis, Emerging Trends and Global Industry Insights appeared first on Gatorledger.
Pediatric Clinical Trials Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Pediatric Clinical Trials Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/397
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc., Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol – Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Shire plc., and Vertex Pharmaceuticals Inc.
Increasing regulatory approvals of new pediatric drugs is expected to augment the market growth.
Key players in the market are focused on launching and approval of novel pediatric drugs, in order to cater to unmet needs of pediatric patients, which are expected to boost the market growth. Moreover, robust product pipeline is expected to drive the market growth. For instance, in December 2018, Merck and Company received the U.S. Food and Drugs Administration (FDA) approval for its Vaxelis, which is indicated for the treatment of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type B. This helped the company to enhance its product portfolio in the pediatric segment. Additionally, in December 2018, Servier Laboratories received FDA approval for Asparlas (calaspargase pegol-mknl), an asparagine specific enzyme indicated for the treatment of acute lymphoblastic leukemia in pediatrics and young adults, which is expected to help the company to enhance its product portfolio in pediatric therapy segment. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients suffered from diabetes, globally in 2017, of which one million people (children and adolescents below 20 years of age) were suffered from type 1 diabetes, with around 150,000 new cases reported, annually.
Browse 38 Market Data Tables and 34 Figures spread through 277 Pages and in-depth TOC on ‘Pediatric Clinical Trials Market’- Global Forecast to 2026, by Clinical Trial Phase (Pre-clinical, Phase I, Phase II, and Phase III), by Study Design (Interventional, (Randomized Trial, Non-randomized Trial, Crossover Trial) and Observational), by Medical Condition (Neuropsychiatric, Conditions, Infectious Diseases, Maternal and Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer, Digestive Diseases, Diabetes, Nutritional Deficiencies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Major market players are focusing on adopting strategies such as mergers, acquisitions, and collaborations to strengthen their market position. For instance, in April 2017, Charles River entered into a strategic collaboration with Nimbus Therapeutics that is engaged in advancing new programs in immunology, metabolic disorders, and oncology from the discovery phase to Investigational New Drug (IND) submission.
Key Takeaways of the Pediatric Clinical Trials Market:
The global pediatric clinical trials market is expected to exhibit a CAGR of 8.8% over the forecast period, attributed to robust product pipeline and increasing regulatory approval of new pediatric drugs
Among clinical trial phase, pre-clinical segment held a dominant position in the pediatric clinical trials market in 2018, attributed to safety and efficacy concerns about new molecules or drugs, as every new molecule must go through pre-clinical study
Among study design, randomized trial segment held a dominant position in the pediatric clinical trials market in 2018, as randomized trial study design eliminates the chance of biasness in clinical trials and is considered as the most favorable study design
Among medical condition, neuropsychiatric conditions segment held a dominant position in the pediatric clinical trials market in 2018, attributed to increasing number of mental disorders in children and adolescents. Mental disorders mainly affect children below age of 14 years.
Buy This Premium Report Of Pediatric Clinical Trials Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/397
In this study, the years considered to estimate the market size of Pediatric Clinical Trials are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Pediatric Clinical Trials Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Pediatric Clinical Trials Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Pediatric Clinical Trials Market Share Is Estimated to Grow at a CAGR of 9.0% By 2027 | Future Growth Analysis, Emerging Trends and Global Industry Insights appeared first on Gatorledger.
Explore more articles in the Research Reports category
